Filing Details

Accession Number:
0001209191-20-032147
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-05-26 17:57:59
Reporting Period:
2020-05-21
Accepted Time:
2020-05-26 17:57:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1595893 Turning Point Therapeutics Inc. TPTX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1595117 Simeon George C/o S.r.one, Limited
161 Washington Street, Suite 500
Conshohocken PA 19428
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-21 83,333 $60.00 2,253,660 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Footnotes
  1. Reflects shares of Common Stock of Turning Point Therapeutics, Inc (the "Issuer") that were purchased by S.R. One, Limited in connection with the Issuer's public offering.
  2. S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares reported herein. Simeon J. George is the Chief Executive Officer, President and a Member of the Board of Trustees at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Mr. George disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.